Aclaris therapeutics announces inducement grants under nasdaq listing rule 5635(c)(4)

Wayne, pa., jan. 06, 2025 (globe newswire) -- aclaris therapeutics, inc. (nasdaq: acrs) (the “company” or “aclaris”), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that effective january 2, 2025, the compensation committee of aclaris' board of directors (the committee) granted nonstatutory stock options to purchase an aggregate of 215,000 shares of its common stock and 61,000 restricted stock units to 1 new employee under the aclaris therapeutics, inc. 2024 inducement plan (the “2024 inducement plan”).  the stock options and restricted stock units were granted as inducements material to the new employee becoming an employee of aclaris in accordance with nasdaq listing rule 5635(c)(4).
ACRS Ratings Summary
ACRS Quant Ranking